2.13
+0.47%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Atossa Therapeutics
From its filings with the US Securities and Exchange Commission
Atossa Therapeutics is based in Seattle, Washington and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ATOS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2015, it reported revenue of $1,758.
We have been granted U.S. and international patents covering our proprietary (Z)-endoxifen, and we have numerous applications pending in the U.S. and in other major countries. We expect to have patent protection covering our proprietary (Z)-endoxifen through at least November 17, 2038.
Our business strategy is to advance our programs through clinical studies, including with potential partners, and opportunistically add programs in areas of high unmet medical need through acquisition, minority investment, collaboration, or internal development.
(Z)-endoxifen is the most active metabolite of Tamoxifen and is substantially more potent as an estrogen receptor antagonist than Tamoxifen and other approved SERMs. Unlike Tamoxifen, which requires metabolic activation through CYP2D6 and other liver enzymes, (Z)-endoxifen does not require first-pass metabolism to achieve therapeutic concentrations. As a result, its activity is not dependent on patient-specific metabolic variability.
(Z)-endoxifen is a small-molecule oral agent designed to directly inhibit estrogen receptor signaling, induce estrogen receptor degradation, and promote apoptosis in estrogen receptor positive (ER+) breast cancer cells. Preclinical and clinical data suggest that (Z)-endoxifen may inhibit clinically relevant ESR1 mutations associated with resistance to aromatase inhibitors and may also inhibit protein kinase C beta one (PKCβ1), resulting in downregulation of the AKT signaling pathway.
Quoted from its 10-K, filed 25 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Nov 2012
- Employees
- 14
- Website
- atossatherapeutics.com ↗
- Head office
- 1448 NW MARKET STREET, SEATTLE, WA, 98107
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Steven QuayChairman of the Board, President, Chief Executive Officer, since 2009$2.8m
- Ms. Heather ReesChief Financial Officer$1.1m
- Ms. Janet ReaSenior Vice President - R&D
- Mr. H. Lawrence RemmelLead Independent Director$206,842
- Dr. Shu-Chih ChenDirector, since 2009$151,842
- Dr. Tessa CiglerIndependent Director$213,617
- Mr. Jonathan FinnIndependent Director$171,842
- Dr. Stephen GalliIndependent Director$191,842
- Mr. Richard SteinhartIndependent Director$181,842
- Mr. Michael ParksVice President, Investor and Public Relations, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 56
- Environment
- 60
- Social
- 67
- Governance
- 42
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Developing innovative breast cancer therapeutics including Topical Endoxifen and microcatheter technology.
- Focused on clinical-stage development with two key pipeline programs for breast conditions.
- Headquartered in Seattle with a dedicated team of 14 employees in biotechnology.
Weaknesses
- Limited to two pipeline programs with no additional therapeutic candidates in development.
- Currently employs only 14 full-time employees, which may restrict operational capacity.
- Relies solely on clinical-stage development without established commercial products.
Opportunities
- Expanding Topical Endoxifen to address mammographic breast density and gynecomastia prevention.
- Growing demand for targeted breast cancer treatments in the Health Care sector.
- Potential for CAR-T therapy applications using intraductal microcatheter technology.
Threats
- Dependence on clinical-stage development with no revenue from commercial products.
- Regulatory challenges in bringing new therapeutics to market.
- Competition from larger biotechnology firms in breast cancer treatment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.